Document Detail

Aprotinin in cardiac surgery patients: is the risk worth the benefit?
MedLine Citation:
PMID:  19782574     Owner:  NLM     Status:  In-Process    
BACKGROUND: Aprotinin is the only Food and Drug Administration-approved agent to reduce haemorrhage related to cardiac surgery and its safety and efficacy has been extensively studied. Our study sought to compare the efficacy, early and late mortality and major morbidity associated with aprotinin compared with e-aminocaproic acid (EACA) in cardiac surgery operations. METHODS: Between January 2002 and December 2006, 2101 patients underwent coronary artery bypass grafting (CABG), valve surgery or CABG and valve surgery in our institution with the use of aprotinin (1898 patients) or EACA (203 patients). Logistic regression and propensity score analysis were used to adjust for imbalances in the patients' preoperative characteristics. The propensity score-adjusted sample included 570 patients who received aprotinin and 114 who received EACA (1-5 matching). RESULTS: Operative mortality was higher in the aprotinin group in univariate (aprotinin 4.3% vs EACA 1%, p=0.023) but not propensity score-adjusted multivariate analysis (4% vs 0.9%, p=0.16). In propensity score-adjusted analysis, aprotinin was also associated with a lower rate of blood transfusion (38.8% vs 50%, p=0.04), a lower rate of haemorrhage-related re-exploration (3.7% vs 7.9%, p=0.04) and a higher risk of in-hospital cardiac arrest (3.7% vs 0%, p=0.03) and a marginally but not statistically significantly higher risk of acute renal failure (6.8% vs 2.6%, p=0.09). In Cox proportional hazards regression analysis, the risk of late death was higher in the aprotinin compared to EACA group (hazard ratio=4.33, 95% confidence interval (CI)=1.60-11.67, p=0.004). CONCLUSION: Aprotinin decreases the rate of postoperative blood transfusion and haemorrhage-related re-exploration, but increases the risk of in-hospital cardiac arrest and late mortality after cardiac surgery when compared to EACA. Cumulative evidence suggests that the risk associated with aprotinin may not be worth the haemostatic benefit.
Sotiris C Stamou; Mark K Reames; Eric Skipper; Robert M Stiegel; Marcy Nussbaum; Rachel Geller; Francis Robicsek; Kevin W Lobdell
Related Documents :
20038474 - Avoiding cardiopulmonary bypass in extracardiac cavopulmonary connection: does it reall...
9874434 - Randomized trial comparing packed red cell blood transfusion with and without leukocyte...
11103054 - Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in tot...
16117454 - Improved outcomes during cardiac surgery: a multifactorial enhancement of cardiopulmona...
8185744 - Nerve stimulation in patients undergoing hysterectomy under general anaesthesia.
21215434 - The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate an...
Publication Detail:
Type:  Journal Article     Date:  2009-09-25
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  36     ISSN:  1873-734X     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  869-75     Citation Subset:  IM    
Department of Thoracic and Cardiovascular Surgery, Carolinas Heart and Vascular Institute, Carolinas Medical Center, Charlotte, NC 28203, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Comment In:
Eur J Cardiothorac Surg. 2009 Nov;36(5):875-6   [PMID:  19595607 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
Next Document:  UVA and UVB radiation-induced oxidation products of quercetin.